USP22 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.
Alternative names
Deubiquitinating enzyme 22, KIAA1063, UBP22_HUMAN, USP3L, Ubiquitin carboxyl-terminal hydrolase 22, Ubiquitin specific peptidase 22, Ubiquitin specific peptidase 3 like, Ubiquitin specific protease 22, Ubiquitin thioesterase 22, Ubiquitin thiolesterase 22, Ubiquitin-specific-processing protease 22
What's included?
Recommended products
USP22 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- USP22
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
- Zygosity
- Homozygous
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
USP22 also known as ubiquitin-specific protease 22 is an enzyme belonging to the class of deubiquitinating enzymes (DUBs). It is characterized by the ability to remove ubiquitin moieties from target proteins which can alter their stability and function. Carrying an approximate mass of 59 kDa USP22 localizes mainly in the nucleus. Expression of USP22 is widespread across a range of tissues with higher levels identified in tissues exhibiting high proliferative capacity.
- Biological function summary
Removal of ubiquitin by USP22 regulates gene expression by modulating histone modifications. USP22 acts as a part of the Spt-Ada-Gcn5 acetyltransferase (SAGA) complex which plays a significant role in transcriptional regulation. Through its deubiquitinating activity USP22 alters the ubiquitination status of histone proteins thereby impacting chromatin dynamics and gene transcription.
- Pathways
USP22 takes part in critical pathways like the ubiquitin-proteasome system and chromosome structure modulation. Within these processes USP22 closely interacts with proteins such as SAGA complex members and histone H2B. Its activity within this system highlights roles in transcriptional control and cellular growth important for maintaining cellular homeostasis and regulating cell cycle progression.
- Associated diseases and disorders
USP22 shows strong implications in several types of cancer including colorectal and prostate cancer. Abnormal expression levels can alter the transcriptional landscape contributing to tumor progression and metastasis. Further USP22 links to other proteins like MYC in the cancer context highlighting its importance in oncogenic pathways. This connection suggests that targeting USP22 might offer therapeutic potential in treating cancers where its expression is dysregulated.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human USP22 knockout HeLa cell lysate (ab257789)
Lane 1: Wild-type HeLa cell lysate 20 μg
Lane 2: USP22 knockout HeLa cell lysate 20 μg
False colour image of Western blot: Anti-USP22 antibody [EPR18945] staining at 1/2000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-USP22 antibody [EPR18945] ab195289 was shown to bind specifically to USP22. A band was observed at 59 kDa in wild-type HeLa cell lysates with no signal observed at this size in usp22 knockout cell line Human USP22 knockout HeLa cell line ab264888 (knockout cell lysate ab257789). To generate this image, wild-type and usp22 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged.Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.All lanes: Western blot - Anti-USP22 antibody [EPR18945] (Anti-USP22 antibody [EPR18945] ab195289) at 1/2000 dilution
Lane 1: Western blot - Human USP22 knockout HeLa cell lysate (ab257789)
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: USP22 knockout HeLa cell lysate at 20 µg
Lane 2: Western blot - Human USP22 knockout HeLa cell line (Human USP22 knockout HeLa cell line ab264888)
Performed under reducing conditions.
Predicted band size: 60 kDa
Observed band size: 59 kDa
Western blot - Human USP22 knockout HeLa cell lysate (ab257789)
Lane 1: Wild-type HeLa cell lysate 20 μg
Lane 2: USP22 knockout HeLa cell lysate 20 μg
False colour image of Western blot: Anti-USP22 antibody [EPR4352(2)] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-USP22 antibody [EPR4352(2)] ab109435 was shown to bind specifically to USP22. A band was observed at 59 kDa in wild-type HeLa cell lysates with no signal observed at this size in usp22 knockout cell line Human USP22 knockout HeLa cell line ab264888 (knockout cell lysate ab257789). To generate this image, wild-type and usp22 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.All lanes: Western blot - Anti-USP22 antibody [EPR4352(2)] (Anti-USP22 antibody [EPR4352(2)] ab109435) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate
Lane 2: USP22 knockout HeLa cell lysate
Performed under reducing conditions.
Predicted band size: 60 kDa
Observed band size: 59 kDa
Sanger Sequencing - Human USP22 knockout HeLa cell lysate (ab257789)
Homozygous: 1 bp deletion in exon 1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com